Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
Open accessThe DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Abstract
Immunotherapies play critical roles in cancer treatment. However, given that only a few patients respond to immune checkpoint blockades and other immunotherapeutic strategies, more novel technologies are needed to decipher the complicated interplay between tumor cells and the components of the tumor immune microenvironment (TIME). Tumor immunomics refers to the integrated study of the TIME using immunogenomics, immunoproteomics, immune-bioinformatics, and other multi-omics data reflecting the immune states of tumors, which has relied on the rapid development of next-generation sequencing. High-throughput genomic and transcriptomic data may be utilized for calculating the abundance of immune cells and predicting tumor antigens, referring to immunogenomics. However, as bulk sequencing represents the average characteristics of a heterogeneous cell population, it fails to distinguish distinct cell subtypes. Single-cell-based technologies enable better dissection of the TIME through precise immune cell subpopulation and spatial architecture investigations. In addition, radiomics and digital pathology-based deep learning models largely contribute to research on cancer immunity. These artificial intelligence technologies have performed well in predicting response to immunotherapy, with profound significance in cancer therapy. In this review, we briefly summarize conventional and state-of-the-art technologies in the field of immunogenomics, single-cell and artificial intelligence, and present prospects for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Single‐cell‐based technologies have enabled a better dissection of the TME through precise monitoring of cell sub‐populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–303 of 303
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C., & Sherman, L. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.833 · Cited by 256
The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas
COLEY, W. B. (1991) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199101000-00002 · Cited by 254
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Gil Del Alcazar, C. R., Huh, S. J., Ekram, M. B., Trinh, A., Liu, L. L., Beca, F., Zi, X., Kwak, M., Bergholtz, H., Su, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0222 · Cited by 247 · cited 1×
“Using CIBERSORT, Gil Del Alcazar et al. 39 uncovered the difference in the in fi ltrating T cell subpopulation between breast ductal carcinoma in situ (DCIS) and breast invasive ductal carcinomas (IDCs).”
MethodReliable detection of subclonal single-nucleotide variants in tumour cell populations
Gerstung, M., Beisel, C., Rechsteiner, M., Wild, P., Schraml, P., Moch, H., & Beerenwinkel, N. (2012) · Nature Communications · doi:10.1038/ncomms1814 · Cited by 246
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
MHC Class II epitope predictive algorithms
Nielsen, M., Lund, O., Buus, S., & Lundegaard, C. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03268.x · Cited by 236 · cited 1×
“99,100 105 As frequent updates, NetMHCIIpan may be the priority for researchers depending on its competitive performance.”
BackgroundAccurate identification of single-nucleotide variants in whole-genome-amplified single cells
Dong, X., Zhang, L., Milholland, B., Lee, M., Maslov, A. Y., Wang, T., & Vijg, J. (2017) · Nature Methods · doi:10.1038/nmeth.4227 · Cited by 235
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 217
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Nishino, M., Hatabu, H., & Hodi, F. S. (2019) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 211 · cited 2×
“193,194 Due to its poor prognosis, predictive biomarkers are desperately required.”
BackgroundMethodInfluentialSialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
van de Wall, S., Santegoets, K. C. M., van Houtum, E. J. H., Büll, C., & Adema, G. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.001 · Cited by 208 · cited 1×
“18,19 With the development of tumor immunity, the immune context of the TME, i.e., TIME, has been proven to play a decisive role in carcinogenesis, tumor progression, metastasis, recurrence, and potential therapeutic targets making it being the focus of our review.”
BackgroundAn empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data
Shiraishi, Y., Sato, Y., Chiba, K., Okuno, Y., Nagata, Y., Yoshida, K., Shiba, N., Hayashi, Y., Kume, H., Homma, Y., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt126 · Cited by 200
Immune monitoring using mass cytometry and related high-dimensional imaging approaches
Hartmann, F. J., & Bendall, S. C. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0338-z · Cited by 200 · cited 1×
“128,129 Chevrier et al. 130 applied mass cytometry to successfully depict an in-depth atlas of the TIME in clear renal cell carcinoma and correlated immune compositions with clinical features, which has great clinical signi fi cance and could guide follow-up studies.”
BackgroundImmunometabolism in the Single-Cell Era
Artyomov, M. N., & Van den Bossche, J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.09.013 · Cited by 200
Single Cell Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging
Schober, Y., Guenther, S., Spengler, B., & Römpp, A. (2012) · Analytical Chemistry · doi:10.1021/ac301337h · Cited by 194
Survival of DNA HLA-DR typed and matched cadaver kidney transplants
Opelz, G., Mytilineos, J., Scherer, S., Dunckley, H., Trejaut, J., Chapman, J., Middleton, D., Savage, D., Fischer, G. F., Bignon, J. D., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)90540-6 · Cited by 193 · cited 1×
“73,74 Although real-time polymerase chain reaction (PCR) and sequencing-based methods have been the standard HLA typing methods, their low throughput limits their wide application.”
MethodDerivation of HLA types from shotgun sequence datasets
Warren, R. L., Choe, G., Freeman, D. J., Castellarin, M., Munro, S., Moore, R., & Holt, R. A. (2012) · Genome Medicine · doi:10.1186/gm396 · Cited by 192
Introduction to Single‐Cell RNA Sequencing
Olsen, T. K., & Baryawno, N. (2018) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.57 · Cited by 192
Shi, J.-Y., Wang, X., Ding, G.-Y., Dong, Z., Han, J., Guan, Z., Ma, L.-J., Zheng, Y., Zhang, L., Yu, G.-Z., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320930 · Cited by 191
He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., Zhang, H., Huang, Z., Jiang, T., Tian, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000550 · Cited by 190 · cited 1×
“189 Interestingly, researchers have compared the alterations in the radiomic texture (DelRADx) between baseline and post-treatment CT imaging to discriminate responders from nonresponders.”
BackgroundHigh-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
Shao, X. M., Bhattacharya, R., Huang, J., Sivakumar, I. K. A., Tokheim, C., Zheng, L., Hirsch, D., Kaminow, B., Omdahl, A., Bonsack, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0464 · Cited by 185
A Beginner’s Guide to Analysis of RNA Sequencing Data
Koch, C. M., Chiu, S. F., Akbarpour, M., Bharat, A., Ridge, K. M., Bartom, E. T., & Winter, D. R. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0430tr · Cited by 173 · cited 1×
“107 Thus, in the NGS era, the technological advances of immunogenomics greatly promote the development of tumor immunity research.”
BackgroundGadalla, R., Noamani, B., MacLeod, B. L., Dickson, R. J., Guo, M., Xu, W., Lukhele, S., Elsaesser, H. J., Razak, A. R. A., Hirano, N., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00415 · Cited by 172 · cited 1×
“128,129 Chevrier et al. 130 applied mass cytometry to successfully depict an in-depth atlas of the TIME in clear renal cell carcinoma and correlated immune compositions with clinical features, which has great clinical signi fi cance and could guide follow-up studies.”
BackgroundDetecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers
Wang, Q., Jia, P., Li, F., Chen, H., Ji, H., Hucks, D., Dahlman, K. B., Pao, W., & Zhao, Z. (2013) · Genome Medicine · doi:10.1186/gm495 · Cited by 170
Jiang, Y., Wang, H., Wu, J., Chen, C., Yuan, Q., Huang, W., Li, T., Xi, S., Hu, Y., Zhou, Z., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.295 · Cited by 169 · cited 1×
“187,188 A tumor mutational burden radiomics biomarker (TMBRB) was also developed and outperformed the current clinical models in dividing NSCLC patients into high and low tumor mutation burden (TMB) patients who have different clinical outcomes.”
MethodSelf-citationScoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
Klauschen, F., Müller, K.-R., Binder, A., Bockmayr, M., Hägele, M., Seegerer, P., Wienert, S., Pruneri, G., de Maria, S., Badve, S., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.001 · Cited by 168
T cell antigen discovery via trogocytosis
Li, G., Bethune, M. T., Wong, S., Joglekar, A. V., Leonard, M. T., Wang, J. K., Kim, J. T., Cheng, D., Peng, S., Zaretsky, J. M., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0305-7 · Cited by 161 · cited 1×
“253 Coincidently, another cell-based platform utilizing signaling and antigen-presenting bifunctional receptors was established for neoantigen identi fi cation.”
BackgroundLu, Z., Xu, S., Shao, W., Wu, Y., Zhang, J., Han, Z., Feng, Q., & Huang, K. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00126 · Cited by 158
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Ping, Y., Liu, C., & Zhang, Y. (2018) · Protein & Cell · doi:10.1007/s13238-016-0367-1 · Cited by 157
De Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
Wang, S., Qu, Y., Xia, P., Chen, Y., Zhu, X., Zhang, J., Wang, G., Tian, Y., Ying, J., & Fan, Z. (2020) · Cell Research · doi:10.1038/s41422-020-0312-y · Cited by 156
T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
Joglekar, A. V., Leonard, M. T., Jeppson, J. D., Swift, M., Li, G., Wong, S., Peng, S., Zaretsky, J. M., Heath, J. R., Ribas, A., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0304-8 · Cited by 155 · cited 1×
“254 In these cases, cell lines expressing the predicted neoantigens and TCR replaced patient-derived APCs and lymphocytes and realized high-throughput neoantigen selection as burgeoning immunoge-nomics technologies.”
BackgroundZipSeq: barcoding for real-time mapping of single cell transcriptomes
Hu, K. H., Eichorst, J. P., McGinnis, C. S., Patterson, D. M., Chow, E. D., Kersten, K., Jameson, S. C., Gartner, Z. J., Rao, A. A., & Krummel, M. F. (2020) · Nature Methods · doi:10.1038/s41592-020-0880-2 · Cited by 151 · cited 1×
“173,174 Using these technologies to match clustered regions with individual cells, a spatial landscape of the transcriptome can be generated.”
BackgroundAn ensemble approach to accurately detect somatic mutations using SomaticSeq
Fang, L. T., Afshar, P. T., Chhibber, A., Mohiyuddin, M., Fan, Y., Mu, J. C., Gibeling, G., Barr, S. M., Asadi, N. B., Gerstein, M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0758-2 · Cited by 150
Neumann, E. K., Comi, T. J., Rubakhin, S. S., & Sweedler, J. V. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812892 · Cited by 149 · cited 1×
“158 161 Further application of laser ablation coupled with inductively coupled plasma mass spectrometry (LA-ICP-MS) is also limited by the laser spot size, analysis speed, and sensitivity but may be combined with IHC, which we do not discuss in detail here.”
MethodHLA DNA Typing and Transplantation
Erlich, H. A., Opelz, G., & Hansen, J. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00115-7 · Cited by 146 · cited 1×
“73,74 Although real-time polymerase chain reaction (PCR) and sequencing-based methods have been the standard HLA typing methods, their low throughput limits their wide application.”
MethodNolan, J. P., & Condello, D. (2013) · Current Protocols in Cytometry · doi:10.1002/0471142956.cy0127s63 · Cited by 145
do Valle, Í. F., Giampieri, E., Simonetti, G., Padella, A., Manfrini, M., Ferrari, A., Papayannidis, C., Zironi, I., Garonzi, M., Bernardi, S., et al. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1190-7 · Cited by 145 · cited 1×
“65 By integrating VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP in a large web interface, the Genome Variant Investigation Platform (GenomeVIP) provides a new method and has been used in large data projects, such as TCGA PanCanAtlas, to provide high-con fi dence annotated somatic,…”
MethodButterfield, L. H., & 易宗毕 (2015) · doi:10.3760/cma.j.issn.1007-9742.2015.11.117 · Cited by 142
Human Leukocyte Antigen Gene Polymorphism and the Histocompatibility Laboratory
Williams, T. M. (2001) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60658-7 · Cited by 141
Strength of immune selection in tumors varies with sex and age
Castro, A., Pyke, R. M., Zhang, X., Thompson, W. K., Day, C.-P., Alexandrov, L. B., Zanetti, M., & Carter, H. (2020) · Nature Communications · doi:10.1038/s41467-020-17981-0 · Cited by 129
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0020 · Cited by 126 · cited 1×
“196 Altogether, radiomics technology enables the identi fi cation of changes in tumors during an early stage, stratifying patients ’ sensitivity to immunotherapy and predicting their clinical outcomes via a noninvasive method.”
MethodComputational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 122 · cited 1×
“99,100 105 As frequent updates, NetMHCIIpan may be the priority for researchers depending on its competitive performance.”
BackgroundVaidya, P., Bera, K., Patil, P. D., Gupta, A., Jain, P., Alilou, M., Khorrami, M., Velcheti, V., & Madabhushi, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001343 · Cited by 117 · cited 1×
“195 Another response is pseudoprogression, which is de fi ned as an increase in tumor size or newly identi fi ed lesion after treatment is initiated before a decrease in tumor size is observed.”
BackgroundQiao, W., Quon, G., Csaszar, E., Yu, M., Morris, Q., & Zandstra, P. W. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002838 · Cited by 115
Azevedo Tosta, T. A., de Faria, P. R., Neves, L. A., & do Nascimento, M. Z. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2018.10.004 · Cited by 115 · cited 1×
“147,148 However, without speci fi c markers, we can only empirically divide cells into several large subgroups, such as parenchyma cells, fi broblasts, muscle cells, and in fl ammatory cells, which is not suitable for characterizing the spatial architecture of the TIME.”
BackgroundInference of high resolution HLA types using genome-wide RNA or DNA sequencing reads
Bai, Y., Ni, M., Cooper, B., Wei, Y., & Fury, W. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-325 · Cited by 112 · cited 1×
“83 Notably, among these tools, Polysolver enables high-precision HLA typing and is among the currently accepted standard tools using low-coverage WES data, particularly when applied to cancer-associated somatic mutations.”
MethodRobinson, J. P., & Roederer, M. (2015) · Science · doi:10.1126/science.aad6770 · Cited by 112
Arneson, D. V., Yang, X., & Wang, K. (2020) · Communications Biology · doi:10.1038/s42003-020-01146-2 · Cited by 109 · cited 1×
“42 Notably, the combination of NGS data and bioinformatics algorithms could roughly differentiate immune cell types.”
BackgroundHLAscan: genotyping of the HLA region using next-generation sequencing data
Ka, S., Lee, S., Hong, J., Cho, Y., Sung, J., Kim, H.-N., Kim, H.-L., & Jung, J. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1671-3 · Cited by 108
O’Neill, K., Aghaeepour, N., Špidlen, J., & Brinkman, R. R. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003365 · Cited by 106 · cited 1×
“126 However, when deciding how to optimize fl ow cytometry, researchers are often faced with the following dilemma: more measurable parameters with a lower accuracy or a higher accuracy with limited measurable parameters, particularly due to the overlap between the emission spectra of fl uorochromes.”
BackgroundRudnicka, D., Oszmiana, A., Finch, D. K., Strickland, I., Schofield, D. J., Lowe, D. C., Sleeman, M. A., & Davis, D. M. (2013) · Blood · doi:10.1182/blood-2013-02-482570 · Cited by 106 · cited 1×
“209 (4) Immune checkpoint blockades .”
Cheng, J., Hu, Y., Kelly, D. E., Kim, J., Li, M., & Zhang, N. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx754 · Cited by 106 · cited 1×
“135 138 No longer limited by predetermined targets as fl ow cytometry, an individual cell can be sequenced using the standard NGS protocol to obtain unbiased multi-omics pro fi ling that can be used to identify “ THE UNKNOWN UNKNOWN ” .”
MethodHu, Y., Wang, Z., Hu, H., Wan, F., Chen, L., Xiong, Y., Wang, X., Zhao, D., Huang, W., & Zeng, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz427 · Cited by 105
Fang, Y., Mo, F., Shou, J., Wang, H., Luo, K., Zhang, S., Han, N., Li, H., Ye, S., Zhou, Z. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2881 · Cited by 104 · cited 1×
“257,258 269 Immunogenomics approaches have been widely applied in vaccine development in clinical research.”
BackgroundHao, Y., Yan, M., Heath, B. R., Lei, Y. L., & Xie, Y. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006976 · Cited by 103 · cited 1×
“32 FARDEEP relies on the least trimmed square (LTS) to construct a robust model suitable for datasets with heavy-tailed noise.”
MethodPrognostic significance of spatial immune profiles in human solid cancers
Tsujikawa, T., Mitsuda, J., Ogi, H., Miyagawa‐Hayashino, A., Konishi, E., Itoh, K., & Hirano, S. (2020) · Cancer Science · doi:10.1111/cas.14591 · Cited by 103 · cited 1×
“22,223 Initially, quanti fi ed by IHC or fl ow cytometry, the density of TILs was used to re fl ect the intensity of the anti-tumor response.”
MethodHLA-VBSeq: accurate HLA typing at full resolution from whole-genome sequencing data
Nariai, N., Kojima, K., Saito, S., Mimori, T., Sato, Y., Kawai, Y., Yamaguchi-Kabata, Y., Yasuda, J., & Nagasaki, M. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s2-s7 · Cited by 100
Development of a high-resolution NGS-based HLA-typing and analysis pipeline
Wittig, M., Anmarkrud, J. A., Kässens, J. C., Koch, S., Förster, M., Ellinghaus, E., Hov, J. R., Sauer, S., Schimmler, M., Ziemann, M., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv184 · Cited by 100
Krassowski, M., Paczkowska, M., Cullion, K., Huang, T., Dzneladze, I., Ouellette, B. F. F., Yamada, J. T., Fradet-Turcotte, A., & Reimand, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx973 · Cited by 95
Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery
Lee, H., & Kingsford, C. (2018) · Genome Biology · doi:10.1186/s13059-018-1388-2 · Cited by 93 · cited 1×
“84,85 However, considering the complexity of the HLA types, we still expect independent benchmarking studies and more tools to be presented.”
BackgroundFriedenberger, M., Bode, M., Krusche, A., & SCHUBERT, W. J. (2007) · Nature Protocols · doi:10.1038/nprot.2007.320 · Cited by 88
Flow cytometry data analysis: Recent tools and algorithms
Montante, S., & Brinkman, R. R. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13016 · Cited by 87
HLAreporter: a tool for HLA typing from next generation sequencing data
Huang, Y., Yang, J., Ying, D., Zhang, Y., Shotelersuk, V., Hirankarn, N., Sham, P. C., Lau, Y., & Yang, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0145-3 · Cited by 86
PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity
Liu, G., Li, D., Li, Z., Qiu, S., Li, W., Chao, C., Yang, N., Li, H., Cheng, Z., Song, X., et al. (2017) · GigaScience · doi:10.1093/gigascience/gix017 · Cited by 85 · cited 1×
“94 Currently, the industry standard for predicting the pMHC-I binding af fi nity is NetMHCpan-4.”
BackgroundVäyrynen, J. P., Lau, M. C., Haruki, K., Väyrynen, S. A., Dias Costa, A., Borowsky, J., Zhao, M., Fujiyoshi, K., Arima, K., Twombly, T. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0071 · Cited by 83
MHCSeqNet: a deep neural network model for universal MHC binding prediction
Phloyphisut, P., Pornputtapong, N., Sriswasdi, S., & Chuangsuwanich, E. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2892-4 · Cited by 77
Park, C., Na, K. J., Choi, H., Ock, C.-Y., Ha, S., Kim, M., Park, S., Keam, B., Kim, T. M., Paeng, J. C., et al. (2020) · Theranostics · doi:10.7150/thno.50283 · Cited by 71 · cited 1×
“First, radiomics provides a non-invasive method to estimate immune-related biomarkers, such as the cytolytic activity score (CytAct) predicted by the deep learning of fl uorodeoxyglucose positron emission tomography (FDG-PET) 186 and the Immuno-Score of gastric cancer predicted by radiomic features.”
MethodZeng, H., & Gifford, D. K. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.004 · Cited by 67
Rappazzo, C. G., Huisman, B. D., & Birnbaum, M. E. (2020) · Nature Communications · doi:10.1038/s41467-020-18204-2 · Cited by 67
Application of single-cell technology in cancer research
Liang, S.-B., & Fu, L. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.04.001 · Cited by 65 · cited 1×
“134 Single-cell separation, which is also called single-cell isolation, plays an indispensable role in single-cell studies, including FACS, laser microdissection, manual cell picking, random seeding/dilution, and micro fl uidics/lab-on-a-chip devices.”
Buchkovich, M. L., Brown, C., Robasky, K., Chai, S., Westfall, S., Vincent, B. G., Weimer, E. T., & Powers, J. (2017) · Genome Medicine · doi:10.1186/s13073-017-0473-6 · Cited by 62
Toward in silico Identification of Tumor Neoantigens in Immunotherapy
Zhou, C., Zhu, C., & Liu, Q. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.001 · Cited by 57
Comparing the performance of selected variant callers using synthetic data and genome segmentation
Bian, X., Zhu, B., Wang, M., Hu, Y., Chen, Q., Nguyen, C. D., Hicks, B. D., & Meerzaman, D. M. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2440-7 · Cited by 54 · cited 1×
“63,64 How to optimize the present tools and design a versatile and ef fi cient variant caller to better discriminate true variants from sequencing errors is worthy of further research.”
BackgroundVenkatesh, G., Grover, A., Srinivasaraghavan, G., & Rao, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa479 · Cited by 52
A machine-learning approach for accurate detection of copy number variants from exome sequencing
Pounraja, V. K., Jayakar, G., Jensen, M., Kelkar, N., & Girirajan, S. (2019) · Genome Research · doi:10.1101/gr.245928.118 · Cited by 51
HLA techniques: Typing and antibody detection in the laboratory of immunogenetics
Bontadini, A. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.025 · Cited by 45 · cited 1×
“75 In particular, the tools used for HLA typing in the era of NGS have dramatically changed the fi eld.”
MethodComputational approaches for characterizing the tumor immune microenvironment
Liu, C. C., Steen, C. B., & Newman, A. M. (2019) · Immunology · doi:10.1111/imm.13101 · Cited by 45 · cited 1×
“22,119 Therefore, characterizing the TIME and determining the cellular components could be highly bene fi cial for tumor immunity studies.”
BackgroundDiscovery and characterization of actionable tumor antigens
Ehx, G., & Perreault, C. (2019) · Genome Medicine · doi:10.1186/s13073-019-0642-x · Cited by 44
Spectral flow cytometry—Quo vadimus?
Robinson, J. P. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23779 · Cited by 43 · cited 1×
“133 Flow cytometry, mass cytometry, and spectral fl ow cytometry all base on binding a speci fi c label with the corresponding cellular subgroup and identifying that label, indicating that the targets must be determined before sample acquisition.”
BackgroundIdentification of tumor antigens and T-cell epitopes, and its clinical application
Paschen, A., Eichmüller, S. B., & Schadendorf, D. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0479-3 · Cited by 42
Predictive potential and need for standardization of PD-L1 immunohistochemistry
Prince, S. S., & Bubendorf, L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2445-7 · Cited by 40
Krijgsman, D., van Leeuwen, M. B., van der Ven, J., Almeida, V., Vlutters, R., Halter, D., Kuppen, P. J. K., van de Velde, C. J. �., & Wimberger-Friedl, R. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3003475 · Cited by 38
To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy
Thaxton, J. E., & Li, Z. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.973314 · Cited by 37
PyroHMMsnp: an SNP caller for Ion Torrent and 454 sequencing data
Zeng, F., Jiang, R., & Chen, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt372 · Cited by 36
The Antigenicity of the Tumor Cell — Context Matters
Kristensen, V. N. (2017) · New England Journal of Medicine · doi:10.1056/nejmcibr1613793 · Cited by 36 · cited 1×
“1, 97 Using mass spectrometry datasets for model selection, MHC fl urry provides another choice in addition to tools based on ANNs, which have been validated to show competitive accuracy.”
MethodAssessing Immunotherapy with Functional and Molecular Imaging and Radiomics
García‐Figueiras, R., Baleato‐González, S., Luna, A., Iglesias, J. M., Oleaga, L., Casas, J. A. V., Martín‐Noguerol, T., Broncano, J., Areses, M. C., & Vilanova, J. C. (2020) · Radiographics · doi:10.1148/rg.2020200070 · Cited by 34 · cited 2×
“193,194 Due to its poor prognosis, predictive biomarkers are desperately required.”
BackgroundMethodInfluentialZormpas‐Petridis, K., Failmezger, H., Raza, S. E. A., Roxanis, I., Jamin, Y., & Yuan, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01045 · Cited by 30 · cited 1×
“201 Furthermore, predictive models that incorporate the immune cell composition and spatial organization correlate with cancer prognosis, which several groups have proven in colorectal cancer, HCC, and melanoma 202 – 205 (Fig.”
BackgroundNomenclature for factors of the HLA system, update July 1995
Marsh, S. G. E. (1995) · Tissue Antigens · doi:10.1111/j.1399-0039.1995.tb02508.x · Cited by 28
NITUMID: Nonnegative matrix factorization-based Immune-TUmor MIcroenvironment Deconvolution
Tang, D., Park, S., & Zhao, H. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz748 · Cited by 26
Concept of Immunomics: A New Frontier in the Battle for Gene Function?
Kłysik, J. (2001) · Acta Biotheoretica · doi:10.1023/a:1011901410166 · Cited by 24 · cited 1×
“13,14 Next-generation sequencing (NGS) technologies greatly promote the development of immunogenomics, an important branch of immunomics.”
BackgroundGenomeVIP: a cloud platform for genomic variant discovery and interpretationPreprint
Mashl, R. J., Scott, A. D., Huang, K.-L., Wyczalkowski, M. A., Yoon, C. J., Niu, B., DeNardo, E. K., Yellapantula, V. D., Handsaker, R. E., Chen, K., et al. (2017) · Genome Research · doi:10.1101/gr.211656.116 · Cited by 23 · cited 1×
“66,67 Furthermore, it is advisable to select more than two tools to predict abnormal proteins in practice.”
BackgroundQuantitative biology of single neurons
Eberwine, J. H., Lovatt, D., Buckley, P. T., Dueck, H., Francis, C., Kim, T. K., Lee, J., Lee, M. T., Miyashiro, K., Morris, J. F., et al. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0417 · Cited by 19
Single‐cell technologies in reproductive immunology
Vázquez, J., Ong, I. M., & Stanic, A. K. (2019) · American Journal of Reproductive Immunology · doi:10.1111/aji.13157 · Cited by 16
Nomenclature for factors of the HLA system, update April, May, and June 2020
Marsh, S. G. E. (2020) · HLA · doi:10.1111/tan.14000 · Cited by 15
Immunomics in Pediatric Rheumatic Diseases
Tay, S. H., Yaung, K. N., Leong, J. Y., Yeo, J. G., Arkachaisri, T., & Albani, S. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00111 · Cited by 9
Nomenclature for factors of the HLA system, update April, May and June 2020
Marsh, S. G. E. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12510 · Cited by 8 · cited 1×
“71 Different HLAs have distinct binding af fi nities to abnormal proteins.”
BackgroundElemental and molecular imaging by LA-ICP-MS
Fernández, B. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1523-7 · Cited by 6 · cited 1×
“156,162 Notably, the onset of multiplexed ion beam imaging by time-of-fl ight (MIBI-TOF) had an impact on this fi eld.”
BackgroundChelvanambi, S., Hester, J., Sharma, S., Lahm, T., & Frump, A. L. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0333ro · Cited by 5
Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time
Fisher, D. A. C., & Oh, S. T. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1538 · Cited by 5 · cited 1×
“158 161 Further application of laser ablation coupled with inductively coupled plasma mass spectrometry (LA-ICP-MS) is also limited by the laser spot size, analysis speed, and sensitivity but may be combined with IHC, which we do not discuss in detail here.”
MethodRe-claiming H&E: back to the future
Romano, L. A., & Pedrosa, V. F. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136955 · Cited by 4 · cited 1×
“147,148 However, without speci fi c markers, we can only empirically divide cells into several large subgroups, such as parenchyma cells, fi broblasts, muscle cells, and in fl ammatory cells, which is not suitable for characterizing the spatial architecture of the TIME.”
BackgroundKrummel, M. F., Hu, K. H., de Vries, E. G. E., Goetz, J. G., Passaro, D., Subramaniam, S., Misteli, T., Skala, M. C., Bravo‐Cordero, J. J., & Sutcliffe-Goulden, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.014 · Cited by 4 · cited 1×
“173,174 Using these technologies to match clustered regions with individual cells, a spatial landscape of the transcriptome can be generated.”
BackgroundJiang, Y., Wang, H., Wu, J., Chen, C., Yuan, Q., Huang, W., Li, T., Xi, S., Hu, Y., Zhou, Z., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.064 · Cited by 2
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Single-cell-based technologies have enabled a better dissection of the TME through precise monitoring of cell sub-populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
BackgroundArtificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends
Li, Z., Koban, K. C., Schenck, T. L., Giunta, R. E., Li, Q., & Sun, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226826 · Cited by 248
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Zou, J., Wang, L., Tang, H., Liu, X., Peng, F., & Peng, C. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413335 · Cited by 150
“Bioinformatics is a novel analysis technology widely used for the prediction of outcomes in cancer immunotherapy [70].”
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer
Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., Rao, T. N., & Sekar, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01565-1 · Cited by 140
“As a result, NGS technology has become the foundation for developing targeted immunotherapy for cancer, as well as the development of individualized treatment plans for cancer patients [42].”
Zhang, Y., Xu, M., Ren, Y., Ba, Y., Liu, S., Zuo, A., Xu, H., Weng, S., Han, X., & Liu, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01980-6 · Cited by 133
“Imaging histology, as a non-invasive imaging method, has shown great potential in the diagnosis and treatment of tumours by combining learning models with digital pathology [125].”
Method
Metadata
- Authors
- Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Xiao, Yi
- Shao, Zhi-Ming
- Jiang, Yi-Zhou
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-20
- Volume
- 6
- Issue
- 1
- Pages
- 312-312
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8377461
- OpenAlex
- W3194492341
- Cited by
- 163
- References
- 303
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 38 · 2023: 50 · 2022: 16 · 2021: 5
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81874113, 82002792, 81922048, 81874112)
- Fok Ying Tong Education Foundation (171034)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, tumor immune microenvironment, immunogenomics, immunoproteomics, single-cell analysis, artificial intelligence, radiomics, digital pathology, deep learning, immune checkpoint blockade, immunotherapy response prediction, tumor heterogeneity, immune cell subpopulations
- MeSH terms
- Antigens, Neoplasm, Artificial Intelligence, Humans, Immunity, Innate, Immunogenetics, Immunotherapy, Neoplasms, Biomarkers, Tumor, Genome, Human, Cell Lineage, Proteome, Single-Cell Analysis, Tumor Microenvironment, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.